Core Insights - Myriad Genetics has expanded its MyRisk Hereditary Cancer Test to include 100% of genes strongly recommended by national oncology guidelines, enhancing its position in molecular diagnostic testing [1][2][3] Group 1: Test Expansion and Clinical Relevance - The updated MyRisk panel now includes 63 selected genes associated with over 11 cancer types, reflecting the company's commitment to evolving clinical needs [2] - The MyRisk Test is designed to provide clinical value throughout the cancer care continuum, aiding in treatment decisions, surveillance planning, and family risk assessment [3] Group 2: Company Commitment and Expertise - Myriad Genetics emphasizes its expertise in interpreting DNA variants, which significantly impacts patient care, prioritizing genes that influence treatment decisions [3] - The company aims to provide high clinical utility insights to clinicians and genetic counselors, ensuring that the MyRisk Test remains relevant as guidelines evolve [3] Group 3: Accessibility and Integration - Clinicians can conveniently order and review MyRisk Test results through various platforms, including paper forms, the Myriad patient portal, and electronic medical record systems like EPIC and OncoEMR [3]

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover. At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks where Wall Street may be overlooking some imp ...

Core Insights - Myriad Genetics, Inc. announced the presentation of 11 new research studies focused on advancements in oncology and reproductive genetic testing at the NSGC 44 Annual Conference [1][2] - The studies will feature products such as MyRisk Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen [1] Company Commitment - The company emphasizes its commitment to advancing scientific research to improve patient outcomes and provide innovative, data-driven insights for personalized patient care [2] - Myriad Genetics aims to enhance accessibility to genetic testing through collaboration with the genetic counseling community [2] Conference Participation - Myriad Genetics will showcase its latest innovations and support services at booth 317 and through poster presentations during the conference [2] - The presentation schedule includes sessions on November 7 and November 8, 2025 [3] Research Highlights - Key research topics include RNA analysis for interpreting Variants of Uncertain Significance (VUS), fetal fraction amplification for cfDNA screening, and prenatal cell-free DNA screening for maternal colorectal cancer [6] - Additional studies focus on the evolution of genetic screening reports, the spectrum of germline hereditary cancer mutations, and professional development for genetic counselors [6] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, dedicated to improving health and well-being through molecular tests that assess disease risk and guide treatment decisions [4]

Q3 2025 Performance Highlights - Total revenue increased by 13.1% to $2.82 billion[1, 5, 14] - Adjusted diluted EPS reached $2.60 per share[1, 14] - Operating income increased 16.8% to $386 million[14] - Adjusted operating income increased 18.9% to $458 million[14] - Net income attributable to Quest Diagnostics increased 8.5% to $245 million[14] Growth Drivers - Organic revenue growth was 6.8%[5] - Total requisition volume increased by 12.5%[14] - Organic requisition volume increased by 3.9%[14] Strategic Initiatives - Established a lab services joint venture with Corewell Health, expecting Co-Lab Solutions annual revenues to reach approximately $1 billion[6] - Announced Epic as the technology partner for Project Nova[7] 2025 Full Year Guidance - Updated net revenue guidance to $10.96 billion - $11.00 billion, representing an increase of 11.0% - 11.4%[16] - Updated adjusted diluted EPS guidance to $9.76 - $9.84[16]

Core Insights - Myriad Genetics has added two genes, F8 and FXN, to its Foresight Carrier Screen Universal Plus Panel, enhancing its compliance with the American College of Medical Genetics and Genomics recommendations [1][4]. Gene-Specific Information - Variants in the F8 gene are associated with hemophilia A, a hereditary bleeding disorder that can lead to prolonged bleeding [2]. - The FXN gene is linked to Friedreich's ataxia, a rare neurodegenerative disease that causes motor weakness and sensory loss [3]. Product Features and Impact - The Foresight Carrier Screen is designed to provide vital genetic insights for informed family planning, with a detection rate of one in 22 couples for serious inherited conditions [6]. - The Foresight Carrier Screen has been validated through over 20 peer-reviewed publications and is the only expanded carrier screening test with published analytical validation in the US [5]. Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on improving patient care and reducing healthcare costs through molecular insights [7].

Core Viewpoint - QuidelOrtho Corporation is expanding its QUICKVUE portfolio with the introduction of the QUICKVUE Influenza + SARS Test, aimed at enhancing point-of-care diagnostic testing capabilities for respiratory illnesses [1][3]. Product Features and Benefits - The QUICKVUE Influenza + SARS Test allows for rapid, simultaneous detection of influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample, providing results in as fast as 10 minutes [2][5]. - This test is designed for use in various healthcare settings, including physician office laboratories, urgent care centers, emergency departments, and pharmacies, facilitating timely treatment decisions and improved patient outcomes [2][3]. - The test is a CLIA-waived, 510(k)–cleared immunoassay, emphasizing its reliability and efficiency in differentiating between COVID-19 and seasonal flu infections [1][3]. Market Position and Strategy - The launch of the QUICKVUE Influenza + SARS Test reinforces QuidelOrtho's leadership in point-of-care respiratory testing and expands its portfolio of respiratory solutions [3][4]. - The company aims to provide healthcare professionals with cost-effective solutions that streamline clinical decisions and manage seasonal surges in respiratory infections [3][4]. - QuidelOrtho's commitment to innovation is evident in its continuous development of diagnostic solutions that improve patient outcomes across various healthcare settings [4].

Core Insights - Telo Genomics presented a new methodology for minimal residual disease (MRD) assessment at the 22nd International Myeloma Society Annual Meeting, highlighting its innovative approach in the field of multiple myeloma diagnostics [1][2][4] Company Overview - Telo Genomics is a biotech company specializing in diagnostic and prognostic tests through telomere analysis, with a focus on liquid biopsies and related technologies in oncology and neurological diseases [5] - The company aims to improve patient care by developing accurate products that cater to the needs of pathologists, clinicians, academic researchers, and drug developers [5] MRD Methodology - The presented abstract details a new workflow for MRD evaluation that integrates the enumeration and immunophenotyping of individual Multiple Myeloma Circulating Tumor Cells (CTCs) with the TeloView® 3D telomere profiling platform [3] - This method utilizes peripheral blood for CTC evaluation, offering a less invasive biomarker for continuous patient monitoring, and provides actionable insights on disease progression risk [3] Market Context - The MRD testing industry is expected to experience significant growth, with the global market projected to reach USD 4.1 billion by 2032 [6] - The FDA's acceptance of MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies indicates a shift towards more personalized healthcare and faster drug approvals [6] Multiple Myeloma Insights - Multiple Myeloma is the second most common blood cancer, with approximately 35,000 new cases annually in the US and around 180,000 patients undergoing treatment at any given time [8] - The introduction of next-generation therapies has improved the median survival rate to over 5 years, yet the disease remains incurable [8] - Identifying patients at risk of rapid progression to symptomatic MM is a critical clinical need, as treatment costs can reach up to $150,000 per year per patient [8]

Core Viewpoint - QuidelOrtho Corporation (NASDAQ:QDEL) is recognized as one of the best small-cap stocks to buy, with RBC Capital raising its price target from $60 to $62 while maintaining a Buy rating [1][3]. Financial Performance and Strategy - QuidelOrtho has successfully completed a series of transactions to refinance its debt structure, extending debt maturities and reducing required amortization payments, which enhances financial flexibility [2][3]. - The company prioritizes reducing total debt and net debt leverage, improving debt covenant terms, and enhancing cash flow to support future growth [3]. Market Growth and Opportunities - The company has experienced significant growth in international markets during Q2 FY2025, particularly in Latin America, Japan, Asia Pacific, and EMEA regions [4]. - QuidelOrtho is focusing on its molecular strategy, including the acquisition of LEX Diagnostics, which is expected to enhance its growth potential [4]. Analyst Insights - As of September 5, the average price target for QuidelOrtho is $37.50, indicating an upside potential of approximately 30.75% from current levels [5]. - QuidelOrtho operates in various segments, including Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics [5].

Core Insights - Myriad Genetics announced the publication of a study in The Lancet Oncology, showcasing the effectiveness of its Precise MRD test for patients with oligometastatic clear-cell renal cell carcinoma (ccRCC) [1][4] Study Findings - The study aimed to assess the benefits of ultrasensitive MRD testing in oligometastatic ccRCC patients, revealing that circulating tumor DNA (ctDNA) levels correlate with responses to metastasis-directed radiation therapy (MDT) [2][3] - The Precise MRD test successfully detected ctDNA in patients with low tumor burden, potentially allowing them to delay or avoid systemic treatments, thus reducing side effects and enabling treatment de-escalation [2][3] Key Metrics - In the Phase 2 trial, patients who were ctDNA negative experienced nearly double the median systemic therapy-free survival compared to ctDNA positive patients [3] - 94% of patients tested at baseline had ctDNA levels below 100 ppm, indicating the effectiveness of the ultrasensitive testing [7] - Patients who tested negative for ctDNA maintained MDT for a median of 54 months, while those who tested positive progressed to systemic therapy within a median of 27 months [7] - Overall survival rates for ctDNA negative patients on MDT were 94% at two years and 87% at three years [7] Test Overview - Myriad's Precise MRD Test utilizes whole genome sequencing to monitor numerous tumor-specific variants, providing high sensitivity and quantification of ctDNA in cancer patients [5] - The test can be employed throughout a patient's clinical journey, starting from diagnosis and continuing through treatment [5] Company Background - Myriad Genetics specializes in molecular diagnostic testing and precision medicine, aiming to enhance health and well-being through advanced genetic and genomic testing solutions [8]

Core Insights - Myriad Genetics announced a meta-analysis showing that the GeneSight Psychotropic test significantly improves response and remission rates in patients with major depressive disorder (MDD) compared to treatment as usual (TAU) [1][2][3] Study Details - The meta-analysis included six prospective controlled studies with a total of 3,532 adults with MDD who had experienced at least one treatment failure [4] - Response was defined as a 50% or greater improvement in depression scores, while remission was defined as a score of seven or less on the Hamilton Depression Rating Scale (HAM-D17) or five or less on the Patient Health Questionnaire (PHQ-9) [4] GeneSight Test Overview - The GeneSight Psychotropic test analyzes how a patient's genes may affect their response to 64 commonly prescribed psychiatric medications, aiming to reduce the trial-and-error process in medication management [5] Company Background - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on improving patient care and reducing healthcare costs through molecular insights [6]